ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
1541
Rang in Aktien
#19248
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily... ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently undergoing clinical investigation. This lead candidate is being evaluated for its efficacy across a broad spectrum of malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). Beyond its primary program, the company boasts a robust portfolio of experimental therapies. These comprise IMM0306, a bispecific CD47×CD20 molecule aimed at relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, another bispecific agent combining CD47 and HER2 for solid tumors that are either HER2-positive or HER2-low expressing; and IMM2520, a bispecific CD47×PD-L1 molecule intended for various solid tumors. Further development efforts include IMM47, a humanized monoclonal antibody designed to target CD24 for cancer treatment; MM4701, a distinct bispecific molecule simultaneously engaging both CD47 and CD24; IMM2510, a bispecific "mAb-Trap" engineered to block both VEGF and PD-L1; IMM27M, a CTLA-4 antibody enhanced for ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody also featuring augmented ADCC activity. The company was established in 2015 and is headquartered in Shanghai, China.
Aktienkurs
$0.38122017
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$159.74M
Veränderung (1 Tag)
2.58%
Veränderung (1 Jahr)
-71.65%
Land
CN
Handel ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541)
Kategorie
Healthcare
Marktkapitalisierung von ImmuneOnco Biopharmaceuticals (Shanghai) Inc.(1541)
Marktkapitalisierung: $159.74M
Mit Stand October 2026 hat ImmuneOnco Biopharmaceuticals (Shanghai) Inc. eine Marktkapitalisierung von $159.74M. Das macht ImmuneOnco Biopharmaceuticals (Shanghai) Inc. laut unseren Daten zum 19248th wertvollsten Unternehmen der Welt nach Marktkapitalisierung. Die Marktkapitalisierung ist der Gesamtmarktwert aller ausstehenden Aktien eines börsennotierten Unternehmens und wird häufig verwendet, um den Unternehmenswert zu bestimmen.
Marktkapitalisierung von ImmuneOnco Biopharmaceuticals (Shanghai) Inc. von 2023 bis 2026
1541 im Vergleich zu den Top 5 der beliebtesten stocks
| Preis für 1541 | Vermögenswert B | Marktkapitalisierung von B | Ergebnisse | |
|---|---|---|---|---|
$12,615.77
$159.74M
|
$5.286T | +3,309,213.34% | ||
|
$11,914.32
$159.74M
|
$4.993T | +3,125,212.12% | ||
|
$9,953.27
$159.74M
|
$4.171T | +2,610,798.95% | ||
|
$9,479.44
$159.74M
|
$3.972T | +2,486,506.24% | ||
|
$6,779.35
$159.74M
|
$2.841T | +1,778,229.03% |
